Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

519
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

564
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
564
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

609
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

671
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Interleukin-6 is critical in the development of pulmonary vascular disease in <i>Gcn2-</i>deficient mice.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

Canadian journal of physiology and pharmacology·2026
Same author

International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.

Pharmacological reviews·2026
Same author

Placental apelin expression is low in early-onset fetal growth restriction but there is no association between maternal circulating apelin and pregnancy outcome.

Placenta·2026
Same author

3D Brachial Plexus Neurography With Variable-Rate Selective Excitation RF Pulses.

Journal of magnetic resonance imaging : JMRI·2026
Same author

A MR Fingerprinting Development Kit for Quantitative 3D Brain Imaging.

Journal of magnetic resonance imaging : JMRI·2026

関連する実験動画

Updated: Mar 8, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K

エラベラ/ トッドラーは,成人の心血管系におけるアペリンAPJ受容体の内生性アゴニストであり,ペプチドの外生的な投与は,肺動脈高血圧におけるその発現の低下を補償する.

Peiran Yang1, Cai Read1, Rhoda E Kuc1

  • 1From Experimental Medicine and Immunotherapeutics, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, UK (P.Y., C.R., R.E.K., J.J.M., A.P.D.); Wolfson Brain Imaging Centre, Department of Clinical Neuroscience, University of Cambridge, UK (G.B., S.J.S., T.A.C.); Department of Pathology, Papworth Hospital, Papworth Everard, Cambridge, UK (M.S.); Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, UK (R.T., R.C.G.); Department of Medicine, University of Cambridge, Addenbrooke's Hospital, UK (P.D.U., A.C., N.W.M.); and Biomolecular Medicine, Department of Surgery and Cancer, Imperial College, London, UK (R.C.G.).

Circulation
|February 1, 2017
PubMed
まとめ

エラベラ (ELA) はアペリン受容体に対してアペリンと同様の作用をします. ELAは肺動脈高血圧 (PAH) で減少し,ELA治療はラットモデルでPAHを改善した.

キーワード:
エラベラ / トッドラーアペリン心肺疾患肺高血圧Gタンパク質結合の受容体

さらに関連する動画

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.9K
Murine Model of Thoracic Aortic Dissection Induced by Oral &#946;-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

999

関連する実験動画

Last Updated: Mar 8, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.9K
Murine Model of Thoracic Aortic Dissection Induced by Oral &#946;-Aminopropionitrile and Subcutaneous Angiotensin II Infusion
05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

999

科学分野:

  • 心血管生物学
  • 内分泌学
  • 薬理学について

背景:

  • エラベラ (ELA) はアペリン受容体を通して作用する心臓発育に不可欠なペプチドです.
  • 構造的な違いにもかかわらず,ELAは確立されたリガンドアペリンと機能的な類似性を共有しています.
  • 肺動脈高血圧 (PAH) ではアペリン信号が低下することが知られている.

研究 の 目的:

  • ELAペプチドの薬理学,発現,および成人における心血管機能を調査する.
  • PAHのELA変化とその潜在的な治療効果を調査する.
  • ネズミのモデルでPAHの重症度を軽減する ELAの有効性を実証する.

主な方法:

  • ELA受容体相互作用を特徴付けるために,シリコドッキング,結合測定,および細胞シグナリング研究で使用された.
  • ヒトとネズミの心血管組織とプラズマにおけるELA発現は,qPCR,免疫光および免疫測定を用いて評価された.
  • ネズミの急性心臓効果をMRIと心臓キャセテリゼーションで評価し,PAHモデルにおけるELAの役割と治療の可能性を調査した.

主要な成果:

  • ELAはアペリン受容体と結合し,Gタンパク質とβ-アレスティンの経路を活性化し,アペリンとの結合部位が重なり合っている.
  • ELAはアペリンと同様の心血管効果を示し,心臓の収縮性と血管拡張が増加した.
  • 人とネズミのPAHモデルでは,ELA発現の減少が観察された.

結論:

  • ELAは内在的なアペリン受容体アゴニストで,心血管に重大な影響を及ぼし,PAHでダウンレギュレートされる.
  • 外因的なELAペプチド投与は,PAHのラットモデルにおける心肺改造の重症性を効果的に低下させた.
  • これらの発見は,ヒトのPAH治療のためのELAを含むアペリン受容体アゴニストの治療可能性を支持しています.